MicroRNA-381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase-2

Song,Kaiyou; Li,Lianting; Sun,Guiling; Wei,Yanjin

doi:10.3892/etm.2018.5947

MicroRNA-381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase-2

Authors:
- Kaiyou Song
- Lianting Li
- Guiling Sun
- Yanjin Wei
View Affiliations

Affiliations: Department of Cardiology, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China
Published online on: March 12, 2018 https://doi.org/10.3892/etm.2018.5947
Pages: 4557-4563

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to measure the levels of microRNA‑381 (miR‑381) in the plaque tissues, peripheral blood mononuclear cells (PBMCs) and serum of patients with coronary atherosclerosis. In addition, the regulatory mechanisms of miR-381 and cyclooxygenase (COX)‑2 in coronary atherosclerosis were investigated. A total of 36 patients with coronary atherosclerosis who received coronary endarterectomy at Linyi People's Hospital and Junan Hospital of Traditional Chinese Medicine (Linyi, China) between January 2013 and June 2016 were enrolled into the present study, while 39 healthy subjects were included as the control group. Peripheral blood was collected form all patients and healthy subjects. Plaque tissues were resected from patients with coronary atherosclerosis and adjacent artery intimal tissues were resected as the control tissues. Using quantitative polymerase chain reaction, the levels of miR‑381 and COX‑2 mRNA in the plaque tissues, PBMCs and serum were determined. In addition, COX‑2 protein expression in the plaque tissues and PBMCs was measured by western blotting, while enzyme‑linked immunosorbent assay was utilized to examine the protein content in the serum. To identify the direct interaction between miR‑381 and COX‑2 mRNA, dual‑luciferase reporter assay was also conducted. The levels of COX‑2 mRNA and protein in the plaque tissues, PBMCs and serum of patients with coronary atherosclerosis were significantly elevated compared with those in the corresponding control groups. However, the expression of miR‑381 was significantly reduced in the coronary atherosclerosis patients. Dual‑luciferase reporter assay revealed that miR‑381 was able to directly target the 3'‑untranslated region of COX‑2 mRNA to regulate the expression of COX‑2. Therefore, the present study demonstrated that enhanced levels of COX‑2 expression in patients with coronary atherosclerosis are associated with the downregulation of miR‑381 expression, while miR‑381 may regulate the occurrence and immune responses of coronary atherosclerosis via COX-2.

View Figures

View References

1	Alexy T, Pais E, Wenby RB, Mack WJ, Hodis HN, Kono N, Wang J, Baskurt OK, Fisher TC and Meiselman HJ: Abnormal blood rheology and chronic low grade inflammation: Possible risk factors for accelerated atherosclerosis and coronary artery disease in Lewis negative subjects. Atherosclerosis. 239:248–251. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kucharska-Newton AM, Heiss G, Ni H, Stearns SC, Puccinelli-Ortega N, Wruck LM and Chambless L: Identification of heart failure events in medicare claims: The atherosclerosis risk in communities (ARIC) study. J Card Fail. 22:48–55. 2016. View Article : Google Scholar : PubMed/NCBI
3	Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, et al: From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation. 108:1664–1672. 2003. View Article : Google Scholar : PubMed/NCBI
4	Jiang XI, Luo Y, Zhao S, Chen Q, Jiang C, Dai Y, Chen Y and Cao Z: Clinical significance and expression of microRNA in diabetic patients with erectile dysfunction. Exp Ther Med. 10:213–218. 2015. View Article : Google Scholar : PubMed/NCBI
5	Jia W, Wu Y, Zhang Q, Gao GE, Zhang C and Xiang Y: Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring. Mol Clin Oncol. 3:851–858. 2015. View Article : Google Scholar : PubMed/NCBI
6	Graziano A, Lo Monte G, Piva I, Caserta D, Karner M, Engl B and Marci R: Diagnostic findings in adenomyosis: A pictorial review on the major concerns. Eur Rev Med Pharmacol Sci. 19:1146–1154. 2015.PubMed/NCBI
7	Tang Y, Zhang YC, Chen Y, Xiang Y, Shen CX and Li YG: The role of miR-19b in the inhibition of endothelial cell apoptosis and its relationship with coronary artery disease. Sci Rep. 5:151322015. View Article : Google Scholar : PubMed/NCBI
8	Ouimet M, Ediriweera HN, Gundra UM, Sheedy FJ, Ramkhelawon B, Hutchison SB, Rinehold K, van Solingen C, Fullerton MD, Cecchini K, et al: MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J Clin Invest. 125:4334–4348. 2015. View Article : Google Scholar : PubMed/NCBI
9	Ross R: The pathogenesis of atherosclerosis-an update. N Engl J Med. 314:488–500. 1986. View Article : Google Scholar : PubMed/NCBI
10	Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
11	Oguz N, Kirca M, Cetin A and Yesilkaya A: Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells. J Recept Signal Transduct Res. 37:500–505. 2017. View Article : Google Scholar : PubMed/NCBI
12	Rumzhum NN and Ammit AJ: Cyclooxygenase 2: Its regulation, role and impact in airway inflammation. Clin Exp Allergy. 46:397–410. 2016. View Article : Google Scholar : PubMed/NCBI
13	Schonbeck U, Sukhova GK, Graber P, Coulter S and Libby P: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 155:1281–1291. 1999. View Article : Google Scholar : PubMed/NCBI
14	Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH and Polak JM: Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 19:646–655. 1999. View Article : Google Scholar : PubMed/NCBI
15	Dursunoglu N, Dursunoglu D, Yildiz AI, Uludag B, Alaçam ZN and Sarıçopur A: Severity of coronary atherosclerosis in patients with COPD. Clin Respir J. 11:751–756. 2017. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Alhouayek M and Muccioli GG: COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci. 35:284–292. 2014. View Article : Google Scholar : PubMed/NCBI
18	Motino O, Agra N, Contreras Brea R, Domínguez-Moreno M, García-Monzón C, Vargas-Castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, et al: Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. Biochim Biophys Acta. 1862:1710–1723. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kim HJ, Yim GW, Nam EJ and Kim YT: Synergistic effect of COX-2 inhibitor on paclitaxel-induced apoptosis in the human ovarian cancer cell line OVCAR-3. Cancer Res Treat. 46:81–92. 2014. View Article : Google Scholar : PubMed/NCBI
20	Ross S, Eikelboom J, Anand SS, Eriksson N, Gerstein HC, Mehta S, Connolly SJ, Rose L, Ridker PM, Wallentin L, et al: Association of cyclooxygenase-2 genetic variant with cardiovascular disease. Eur Heart J. 35:2242–2248a. 2014. View Article : Google Scholar : PubMed/NCBI
21	More AS, Kim HM, Zhao R, Khang G, Hildebrandt T, Bernlöhr C, Doods H, Lee D, Lee SH, Vanhoutte PM and Wu D: COX-2 mediated induction of endothelium-independent contraction to bradykinin in endotoxin-treated porcine coronary artery. J Cardiovasc Pharmacol. 64:209–217. 2014. View Article : Google Scholar : PubMed/NCBI
22	Papageorgiou N, Zacharia E, Briasoulis A, Charakida M and Tousoulis D: Celecoxib for the treatment of atherosclerosis. Expert Opin Investig Drugs. 25:619–633. 2016. View Article : Google Scholar : PubMed/NCBI
23	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
24	Chen K and Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 8:93–103. 2007. View Article : Google Scholar : PubMed/NCBI
25	Liu D, Wang D, Xu Z, Gao J, Liu M, Liu Y, Jiang M and Zheng D: Dysregulated expression of miR-101b and miR-26b lead to age-associated increase in LPS-induced COX-2 expression in murine macrophage. Age (Dordr). 37:972015. View Article : Google Scholar : PubMed/NCBI
26	Liang Y, Zhao Q, Fan L, Zhang Z, Tan B, Liu Y and Li Y: Down-regulation of MicroRNA-381 promotes cell proliferation and invasion in colon cancer through up-regulation of LRH-1. Biomed Pharmacother. 75:137–141. 2015. View Article : Google Scholar : PubMed/NCBI
27	Liang HQ, Wang RJ, Diao CF, Li JW, Su JL and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381 and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget. 6:29413–29427. 2015. View Article : Google Scholar : PubMed/NCBI
28	Xu Y, Ohms SJ, Li Z, Wang Q, Gong G, Hu Y, Mao Z, Shannon MF and Fan JY: Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. PLoS One. 8:e820622013. View Article : Google Scholar : PubMed/NCBI
29	Chen B, Duan L, Yin G, Tan J and Jiang X: Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells-Cdc2 activity is up-regulated by targeting WEE1. Clinics (Sao Paulo). 68:825–833. 2013. View Article : Google Scholar : PubMed/NCBI
30	Rothschild SI, Tschan MP, Jaggi R, Fey MF, Gugger M and Gautschi O: MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J Thorac Oncol. 7:1069–1077. 2012. View Article : Google Scholar : PubMed/NCBI